On October 31, 2024, livzon pharmaceutical group inc. (000513.SZ) stated during a specific survey that its traditional chinese medicine preparations achieved a revenue of 1.041 billion yuan in the first three quarters, a year-on-year decrease of 16.49%. The main reason for the revenue decline is that at the beginning of last year, the outbreak of the new crown virus, as well as frequent flu after the release, led to good sales of antiviral particles last year. This year, sales of this variety have returned to normal, resulting in a noticeable decline compared to the same period last year.
The company has laid out new product development in the traditional chinese medicine field, exploring multiple projects such as in-house formulations and classic prescriptions. In the long term, several classic prescriptions and traditional chinese compound formulations are expected to be successively reported in the next two years, providing a solid foundation for the future development of the company's traditional chinese medicine.
